These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34428613)

  • 21. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
    Zakout YM; Lanza G
    J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 23. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
    Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
    Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
    Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
    J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
    Reis GF; Pekmezci M; Hansen HM; Rice T; Marshall RE; Molinaro AM; Phillips JJ; Vogel H; Wiencke JK; Wrensch MR; Walsh KM; Perry A
    J Neuropathol Exp Neurol; 2015 May; 74(5):442-52. PubMed ID: 25853694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical Analysis of Mismatch Repair Gene Proteins in Early Gastric Cancer Based on Microsatellite Status.
    Sugimoto R; Endo M; Osakabe M; Toya Y; Yanagawa N; Matsumoto T; Sugai T
    Digestion; 2021; 102(5):691-700. PubMed ID: 33053554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Germline
    Klančar G; Blatnik A; Šetrajčič Dragoš V; Vogrič V; Stegel V; Blatnik O; Drev P; Gazič B; Krajc M; Novaković S
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32197529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of molecular analysis in diffuse glioma stratification.
    Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
    Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated analysis of mismatch repair system in malignant astrocytomas.
    Rodríguez-Hernández I; Garcia JL; Santos-Briz A; Hernández-Laín A; González-Valero JM; Gómez-Moreta JA; Toldos-González O; Cruz JJ; Martin-Vallejo J; González-Sarmiento R
    PLoS One; 2013; 8(9):e76401. PubMed ID: 24073290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    Xi S; Huang Q; Zeng J
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total copy number variation as a prognostic factor in adult astrocytoma subtypes.
    Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE
    Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
    J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
    Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
    Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
    Cimino PJ; Holland EC
    Neuro Oncol; 2019 Jun; 21(6):819-821. PubMed ID: 30918961
    [No Abstract]   [Full Text] [Related]  

  • 37. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
    Fortin Ensign SP; Jenkins RB; Giannini C; Sarkaria JN; Galanis E; Kizilbash SH
    Neuro Oncol; 2023 Jan; 25(1):28-36. PubMed ID: 35973817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
    Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
    World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MMR markers correlate with clinical outcome in patients with esophageal squamous cell carcinoma.
    Yamauchi T; Fujishima F; Tsunokake J; Kunimitsu A; Akaishi R; Ozawa Y; Fukutomi T; Okamoto H; Sato C; Taniyama Y; Kamei T; Ichinohasama R; Sasano H
    Int J Biol Markers; 2023 Jun; 38(2):105-113. PubMed ID: 37009661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.